Latest Administration News

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

The Australian Wealth Advisors Group Ltd (AWAG) reported a 13% revenue increase and a $1.2 million profit before tax in FY2025, driven by strategic Equity Partnership Scheme investments and a strong funds under management base.

GR Engineering Services Limited has announced a fully franked ordinary dividend of AUD 0.12 per share for the half-year ending June 2025, accompanied by a Dividend Reinvestment Plan offering a 2.5% discount.

FAR Limited reported a sharp turnaround to a $1.8 million loss in H1 2025, driven by a $6 million claim from Woodside Energy over its Senegal RSSD Project sale. The company continues negotiations amid volatile oil prices impacting its receivables.

Regal Partners Limited has announced a fully franked ordinary dividend of AUD 0.06 per share for the first half of FY25, alongside a dividend reinvestment plan open to Australian and New Zealand shareholders.

Neuren Pharmaceuticals has initiated the first US investigational site for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, marking a significant milestone in addressing this rare neurodevelopmental disorder.

Haranga Resources has secured regulatory approvals and begun underground works at its Lincoln Gold Project, setting the stage for a maiden drilling campaign aimed at upgrading a significant historical gold resource to JORC standards.

Regis Healthcare delivered a robust FY25 performance with a 14.5% revenue increase and a dramatic turnaround to a $49 million net profit. The company is advancing growth through acquisitions and greenfield developments, positioning itself strongly ahead of upcoming sector reforms.

Praemium Limited reported a robust 25% revenue increase and a 55% jump in net profit for FY2025, driven by strategic client wins and innovative product launches.

Praemium Limited reported robust FY25 results with revenue climbing 24.6% to $103 million and net profit after tax soaring 55% to $13.56 million, underpinned by strong growth in funds under administration and strategic product launches.

Alfabs Australia Limited reported a robust 242% increase in net profit for FY2025 despite a slight dip in revenue, underpinned by strong operational performance and major contract deliveries. The company declared a final dividend, signaling confidence in its financial position.

Ansell Limited has announced an unfranked ordinary dividend of USD 0.28 per share for the six months ending June 2025, accompanied by a Dividend Reinvestment Plan available to select shareholders.